Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Casitas B lymphoma (c-Cbl) is an E3 ubiquitin ligase and a negative regulator of colorectal cancer (CRC). Despite its high expression in immune cells, the effect of c-Cbl on the tumor microenvironment remains poorly understood. Here we demonstrate that c-Cbl alters the tumor microenvironment and suppresses Programmed cell death-1 (PD-1) protein, an immune checkpoint receptor. Using syngeneic CRC xenografts, we observed significantly higher growth of xenografts and infiltrating immune cells in c-Cbl compared to c-Cbl mice. Tumor-associated CD8+ T-lymphocytes and macrophages of c-Cbl mice showed 2-3-fold higher levels of PD-1. Functionally, macrophages from c-Cbl mice showed a 4-5-fold reduction in tumor phagocytosis, which was restored with an anti-PD-1 neutralizing antibody suggesting regulation of PD-1 by c-Cbl. Further mechanistic probing revealed that C-terminus of c-Cbl interacted with the cytoplasmic tail of PD-1. c-Cbl destabilized PD-1 through ubiquitination- proteasomal degradation depending on c-Cbl's RING finger function. This data demonstrates c-Cbl as an E3 ligase of PD-1 and a regulator of tumor microenvironment, both of which were unrecognized components of its tumor suppressive activity. Advancing immune checkpoint and c-Cbl biology, our study prompts for probing of PD-1 regulation by c-Cbl in conditions driven by immune checkpoint abnormalities such as cancers and autoimmune diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934810PMC
http://dx.doi.org/10.1038/s41598-019-56208-1DOI Listing

Publication Analysis

Top Keywords

c-cbl
14
immune cells
12
tumor microenvironment
12
immune checkpoint
12
c-cbl mice
12
pd-1
8
proteasomal degradation
8
cells c-cbl
8
macrophages c-cbl
8
pd-1 c-cbl
8

Similar Publications

S-nitrosylation of pVHL regulates β adrenergic receptor function.

Proc Natl Acad Sci U S A

September 2025

Department of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106.

The β-adrenergic receptor (βAR), a prototype G protein-coupled receptor, controls cardiopulmonary function underpinning O delivery. Abundance of the βAR is canonically regulated by G protein-coupled receptor kinases and β-arrestins, but neither controls constitutive receptor levels, which are dependent on ambient O. Basal βAR expression is instead regulated by the prolyl hydroxylase/pVHL-E3 ubiquitin ligase system, explaining O responsivity.

View Article and Find Full Text PDF

Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay.

J Med Chem

September 2025

Jiang Su Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

Casitas B-lineage lymphoma-b (Cbl-b), a pivotal negative regulator of TCR signaling, is highly expressed in immune cells. Its inhibition potentiates immune-mediated antitumor effects. Herein, we constructed a potent fluorescent tracer, , based on the Cbl-b peptide inhibitor Utilizing this tracer, we established a fluorescence polarization (FP) assay with enhanced sensitivity, discriminative capacity, and precision for the activity evaluation and high-throughput screening of orthosteric Cbl-b Src homology 2 (SH2) domain inhibitors.

View Article and Find Full Text PDF

Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation.

Cell Signal

November 2025

State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China; University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China. Electronic address:

The Cbl-b inhibitor NX-1607 has shown significant antitumor activity and extended survival in murine models; however, its efficacy remains limited in certain patients. In order to expand the clinical application of Cbl-b inhibitors and to provide new therapeutic options for cancer patients with unmet therapeutic needs, we utilized flow cytometry to screen compounds for potentiation in combination with Cbl-b inhibitors and to investigate the mechanism of action of the combination. In this study, we identify that the combination of NX-1607 with the CDK4/6 inhibitor abemaciclib directly augments T cell activation.

View Article and Find Full Text PDF

Background: Rheumatoid arthritis (RA) is a chronic autoimmune condition characterized by persistent inflammation of the joint's synovial membrane. This inflammation leads to the degradation of joint cartilage and bone, resulting in joint dysfunction and deformity. Early symptoms of RA are often subtle, complicating timely diagnosis.

View Article and Find Full Text PDF

Background: HER2-targeted antibody-drug conjugates (ADCs) have shown marked efficacy for HER2 mutation-positive non-small cell lung cancer (NSCLC). The intracellular trafficking of mutant HER2 has remained to be fully elucidated, however.

Methods: HER2 dynamics were examined in cells expressing wild-type (WT) or mutant HER2 with the use of live cell imaging and an in situ proximity ligation assay.

View Article and Find Full Text PDF